Dexcom, Inc. (NASDAQ:DXCM ) Q3 2023 Earnings Conference Call October 26, 2023 4:30 PM ET Company Participants Sean Christensen - Director, Corporate Affairs & Head of IR Kevin Sayer - Executive Cha...

The headline numbers for DexCom (DXCM) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street es...

DexCom (DXCM) came out with quarterly earnings of $0.50 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.28 per share a year ago.

Dexcom topped third-quarter expectations Thursday, shrugging off concerns new weight-loss drugs would undercut its sales. DXCM stock popped.

Shares of DexCom Inc. DXCM, -3.86% shot up 15.3% to pace the S&P 500's SPX, -1.18% after-hours gainers on Thursday, after of maker of glucose monitoring systems reported third-quarter profit that b...

Medical device maker Dexcom on Thursday raised its annual revenue forecast and beat quarterly estimates on strong demand for its continuous glucose monitoring (CGM) devices, sending its shares more...

DexCom's (DXCM) third-quarter 2023 results are likely to reflect rising volumes across all channels.

Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EW, PODD, DXCM and IQV are poised ahead of their earnings release.

DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

DexCom is a big name in diabetes care, and investors may be overly bearish on the stock. InMode recently downgraded its guidance as rising interest rates impact its sales activity.

Plenty of businesses, such as PepsiCo Inc. NYSE: PEP and Walmart Inc. NYSE: WMT, have been under the microscope on fears of potential earnings decreases due to growing use of products like Novo Nor...

When stock-market volatility picks up, investors tend to gravitate to outperforming companies that have enacted stock splits. Nine high-profile companies have conducted forward-stock splits since t...

The latest trading day saw DexCom (DXCM) settling at $80.49, representing a +1.95% change from its previous close.

The dramatic weight loss resulting from a new breed of diabetes medication has weighed on DexCom stock. As with all things, however, the devil is in the details.

This segment originally aired on October 5, 2023 Weight loss drugs, like Novo Nordisk's (NVO) Ozempic, have become popular across healthcare providers in regard to diabetes treatment. Although use ...